5 Stocks Moving The Drugs Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 87 points (0.5%) at 16,266 as of Friday, Dec. 20, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,274 issues advancing vs. 691 declining with 120 unchanged.

The Drugs industry currently sits up 1.4% versus the S&P 500, which is up 0.6%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 6.0%, Regeneron Pharmaceuticals ( REGN), up 1.9%, Celgene Corporation ( CELG), up 1.8%, Amgen ( AMGN), up 1.8% and Biogen Idec ( BIIB), up 1.2%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Jazz Pharmaceuticals ( JAZZ) is one of the companies pushing the Drugs industry higher today. As of noon trading, Jazz Pharmaceuticals is up $6.49 (5.7%) to $121.21 on heavy volume. Thus far, 1.3 million shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 752,700 shares. The stock has ranged in price between $118.16-$126.84 after having opened the day at $125.68 as compared to the previous trading day's close of $114.72.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. Jazz Pharmaceuticals has a market cap of $6.6 billion and is part of the health care sector. The company has a P/E ratio of 21.2, above the S&P 500 P/E ratio of 17.7. Shares are up 115.4% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Jazz Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Allergan ( AGN) is up $4.46 (4.3%) to $108.22 on heavy volume. Thus far, 4.0 million shares of Allergan exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $104.75-$109.89 after having opened the day at $104.75 as compared to the previous trading day's close of $103.76.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $30.1 billion and is part of the health care sector. The company has a P/E ratio of 23.9, above the S&P 500 P/E ratio of 17.7. Shares are up 13.1% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Allergan a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, increase in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Merck ( MRK) is up $0.54 (1.1%) to $49.33 on average volume. Thus far, 6.4 million shares of Merck exchanged hands as compared to its average daily volume of 13.5 million shares. The stock has ranged in price between $48.63-$49.40 after having opened the day at $48.86 as compared to the previous trading day's close of $48.79.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $142.9 billion and is part of the health care sector. The company has a P/E ratio of 32.8, above the S&P 500 P/E ratio of 17.7. Shares are up 19.2% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Merck a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Johnson & Johnson ( JNJ) is up $0.54 (0.6%) to $92.52 on average volume. Thus far, 4.6 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7.3 million shares. The stock has ranged in price between $91.95-$92.58 after having opened the day at $91.95 as compared to the previous trading day's close of $91.98.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $261.4 billion and is part of the health care sector. The company has a P/E ratio of 20.7, above the S&P 500 P/E ratio of 17.7. Shares are up 31.2% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $1.35 (1.8%) to $74.78 on average volume. Thus far, 5.6 million shares of Gilead exchanged hands as compared to its average daily volume of 10.3 million shares. The stock has ranged in price between $73.73-$74.83 after having opened the day at $73.95 as compared to the previous trading day's close of $73.43.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $112.8 billion and is part of the health care sector. The company has a P/E ratio of 40.4, above the S&P 500 P/E ratio of 17.7. Shares are up 100.0% year to date as of the close of trading on Thursday. Currently there are 16 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend

Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers